To guide anti-D prophylaxis, Dutch D-pregnant women are offered a quantitative fetal-RHD-genotyping assay to determine the RHD status of their fetus. This allowed us to determine the frequency of different maternal RHD variants in 37 782 serologically D-pregnant women. A variant allele is present in at least 0Á96% of Dutch D-pregnant women The Dserology could be confirmed after further serological testing in only 54% of these women, which emphasizes the potential relevance of genotyping of blood donors. 43 different RHD variant alleles were detected, including 15 novel alleles (11 null-, 2 partial D-and 2 DEL-alleles). Of those novel null alleles, one allele contained a single missense mutation (RHD*443C>G) and one allele had a single amino acid deletion (RHD*424_426del). The D-phenotype was confirmed by transduction of human D-erythroblasts, consolidating that, for the first time, a single amino acid change or deletion causes the D-phenotype. Transduction also confirmed the phenotypes for the two new variant DEL-alleles (RHD*721A>C and RHD*884T>C) and the novel partial RHD*492C>A allele. Notably, in three additional cases the DEL phenotype was observed but sequencing of the coding sequence, flanking introns and promoter region revealed an apparently wild-type RHD allele without mutations.
The D antigen of the Rh blood group system is one of the most immunogenic and complex blood group antigens (Westhoff, 2007a; Daniels & Reid, 2010) . Most D-individuals lack the complete RhD protein (Colin et al, 1991; Wagner & Flegel, 2000) , which underlies its high immunogenicity. Anti-D can cause severe haemolytic transfusion reactions and/or severe haemolytic disease of the fetus and newborn. To prevent anti-D formation in D-individuals, compatible D-red blood cells (RBCs) are transfused and anti-D prophylaxis is administrated to D-pregnant women (de Haas et al, 2015) .
The Rh locus is highly polymorphic and many RHD variant alleles have been described (Flegel, 2011) . One group of RHD variant alleles, the RHD hybrid alleles, arose due to genetic recombination between the RHD gene and the adjacently located RHCE gene. The second group of RHD variant alleles carry one or multiple mutations in the RHD gene. The genetic variation of the RHD alleles has different effects on the level of expression of RhD protein and the number of expressed RhD epitopes. To date, more than 60 so-called D-null alleles have been described that cause the D-phenotype due to nonsense mutations, frame shift mutations, splice site mutations or to large hybrid alleles (http://www. uni-ulm.de/~fwagner/RH/RB2/P_RHDDnegative.htm). The D-null alleles RHD*03N.01 and RHD*Ψ occur frequently in the D-African population (Flegel, 2011) . RHD positive haplotypes are rare in D-Caucasians (Wagner et al, 2001; Flegel et al, 2005; Chou & Westhoff, 2010) . Individuals with a weak D phenotype express the RhD protein in low quantities, which is most often caused by mutations in the transmembrane regions of the RhD protein (Daniels, 2013a) . Individuals with DEL-allele expression have an even lower amount of the RhD protein on their RBC membrane, which can only be detected with the very sensitive adsorption-elution technique (Okubo et al, 1984) . DEL expression is most often caused by missense mutations causing aberrant splice sites (Reid et al, 2012) . Partial D expression, in which one or more D epitopes are lacking, is most often caused by hybrid alleles or due to mutations in the extracellular parts of the RhD protein. Some partial RHD variant alleles cause partial and weakened expression of the D antigen (Westhoff, 2007b) . The distinction between the different variant alleles is of importance, given that it is unlikely that individuals with weak D or DEL expression produce allo-anti-D, in contrast to individuals with partial D expression who are at risk of D immunization (Daniels, 2013a; Sandler et al, 2015) .
The aim of our study was to determine the frequency of (known and novel) RHD variant alleles in the serologically D-Dutch population. Since July 2011, Dutch D-pregnant women have been offered a quantitative fetal-RHD-genotyping assay to guide anti-D prophylaxis. This quantitative fetal-RHD-genotyping assay is performed with cell-free DNA isolated from maternal plasma, which contains DNA of the fetus (Scheffer et al, 2011; van der Schoot et al, 2013) . However, the large majority of cell free DNA is of maternal origin and, therefore, if a maternal RHD allele is present it will be recognized because it results in much stronger signals in the quantitative polymerase chain reaction (PCR) assay than expected to arise from fetal DNA. In this paper we present the frequency of RHD variant alleles and serological and genetic follow up of cases identified among 37 782 screened Dutch D-pregnant women.
Material and methods

Samples and fetal-RHD-genotyping assay
Between July 2011 and December 2012, 37 782 Dutch serologically D-pregnant women (determined using two anti-D reagents) were tested in the 27th week of pregnancy for the presence of a D+ fetus using a quantitative fetal-RHD-genotyping assay. DNA was isolated from 1 ml of maternal plasma using a DNA isolation kit (DNA and Viral NA Large Volume Kit; Roche Holding AG, Basel, Switzerland) on a MagNa Pure 96 Instrument (Roche) according to the manufacturer's protocol. The quantitative fetal-RHD-genotyping assay has been described previously (Scheffer et al, 2011) and consists of a multiplexed TaqMan test, one targeting RHD exon 5 and one targeting RHD exon 7, performed in triplicate. When at least two of the three Ct values of both assays were below 32, a maternal variant allele was suspected. When at least two of the three Ct values of exon 7 were below 32, but Ct values of exon 5 were either negative or above 32, a RHD*Ψ or RHD*06 maternal variant allele was suspected. In these cases additional genotyping and extended serology was performed to determine whether and which variant allele was present. Of note, the relatively frequently occurring null allele RHD*03N.01 (Daniels et al, 1998) is not amplified and thus not detected in this fetal-RHD-genotyping assay.
Serology
All samples were subjected to column testing on either the Ortho Biovue Inova system (Ortho, Raritan, NJ, USA) with an ABO D card containing anti-D monoclonal antibodies (MoAbs) D7B8, or the Biorad/Diamed Diana system (Bio-Rad Laboratories, Veenendaal, The Netherlands) with an ABO DVI-card, containing anti-D MoAbs LHM59/20 (LDM3) and 175-2. Plasma of all women with a negative result in this serological assay were tested in the fetal-RHDgenotyping assay. A second comprehensive serological assay was performed when a maternal variant allele was suspected. The samples were tested with three monoclonal blend reagents (IgM clone TH28 and IgG clone MS26) (Sanquin Reagents, Amsterdam, The Netherlands and Immucor, Norcross, GA, USA) and IgM clone D7B8, IgG clone H112196 and IgG clone LORIFA (Ortho), and one IgG clone 5C8, a polyclonal IgG reagent (Bio-Rad Laboratories) in an immediate spin at room temperature, in a spin proceeded by 15 min incubation at 37°C and/or by indirect antiglobulin test. If, following this second test, the D-phenotype was suspected and the presence of the RHD*Ψ allele was excluded, absorption-elution was performed using the Gamma â ELU-KIT â II (Immucor) as per manufacturer's protocol using a polyclonal anti-D (Bio-Rad Laboratories) to detect a DEL allele. If the second serological test detected a partial D variant other than the DVI variant, the D-epitope expression of the variant allele was determined using an in-house RhD typing kit consisting of eleven monoclonal IgG antibodies and an additional six MoAbs from the ALBAclone Advanced Partial RhD typing kit (ALBA Bioscience, Edinburgh, UK). These MoAbs were tested in anti IgG + anti C3d gel columns (Bio-Rad laboratories).
RH-MLPA
Maternal DNA was isolated from white blood cells using a DNA extraction kit (QIAamp DNA Blood Mini Kit, Qiagen Benelux, Venlo, The Netherlands). To determine RHD copy number and the presence of RHD variant alleles, DNA samples were analysed with the RH-Multiplex Ligation-dependent Probe Amplification (RH-MLPA) assay (mix p401-A1, p402-A1 and p403-A1, MRC-Holland, Amsterdam, The Netherlands) (Haer-Wigman et al, 2013) . In some cases an RHCE MLPA was performed using RHCE-specific probes to determine the copies of RHCE exons 1, 3, 4, 5, 6, 7, 9 and 10 (probes listed in Table SI ). One case was tested with seven new MLPA probe combinations (targeting c.-698T, c.123A, c.149-4875A, c.149-882G, c.244T, c.335 + 2838C and c.1112G of RHD and RHCE) that were developed to determine the combined RHD and RHCE copy numbers of the 5 0 UTR, exon 1, 2 and 8 and intron 1 and 2 (Table SI) .
The MLPA reaction was performed according to the manufacturer's protocol on a Veriti Thermocycler (Applied Biosystems, Nieuwerkerk aan de IJssel, The Netherlands). A mixture of 1Á0 ll MLPA sample, 8Á5 ll Hi-Di TM Formamide (Applied Biosystems) and 0Á5 ll GeneScan TM 500-Liz â Size Standard (Applied Biosystems) was analysed on a 3130 Genetic Analyser (Applied Biosystems). Data analysis was performed using Genemarker software version 1.85 (Softgenetics, State College, PA, USA).
DNA sequencing
When indicated, all exons and intron boundaries of RHD were sequenced and/or the promoter region of RHD was sequenced (hg19, chr.1:g.25597899_25598887; primer sequences are shown in Supplementary Table SI or as published previously (Haer-Wigman et al, 2013) . The PCR was performed on a Veriti thermocycler in a total volume of 20 ll, containing 50-100 ng DNA, 10 ll of 29 GeneAmp Fast PCR Master Mix (Applied Biosystems), 0Á5 lmol/l forward and reverse primer. PCR conditions were: 10 s at 95°C, 35 cycles of 10 s at 95°C and a specific annealing/elongation temperature and time for each primer set ranging from 62 to 70°C, followed by 1 min at 72°C. PCR products were purified using ExoSAP-IT (GE Healthcare, Eindhoven, The Netherlands), according to the manufacturer's protocol. PCR products were sequenced with ABI BigDye Terminator v3.1 kit on an ABI 3130XL sequencer (Applied Biosystems).
Heterologous transfection system
The RHD coding sequence flanked by a BamH1 and Not1 digestion site was ordered from Invitrogen (Breda, The Netherlands) and cloned into a lentiviral vector containing IRES-GFP for bicistronic gene expression driven under the EF1a promoter. The c.424-426del, c.443G, c.492A, c.721C and c.1154C mutations were mutated into the wild-type RHD construct using QuickChange II XL Site-Directed Mutagenesis Kit (Agilent, Amstelveen, The Netherlands) according to the manufacturer's protocol (Table SI) . Lentivirus was produced by transfecting 293T cells with helper plasmids using the Calcium Phosphate method (Sambrook & Russel, 2001) . The supernatant containing the virus particles was then harvested for 3 days and concentrated through ultracentrifugation. Erythroblast from five different D-(ccddee) donors were cultured from peripheral blood mononuclear cells according to the protocol described by van den Akker et al (2010) and kept in expansion medium for 2-3 d. Erythroblasts were then lentivirally transduced with the RHD wild-type construct or the different variant constructs. After 48-h transduction, cells were transferred into StemSpan medium (Stem Cell technologies, Grenoble, France) supplemented with stem cell factor (SCF; supernatant equivalent to 100 ng/ml), erythropoietin (10 l/ml, ProSpec; East Brunswick, NJ, USA), holotransferrin (0Á5 mg/ml; Sigma-Aldrich, Zwijndrecht, The Netherlands) and insulin (10 mg/ml; Sigma-Aldrich) in order to allow cell differentiation (van den Akker et al, 2010).
Cells were harvested within 5 days of differentiation and screened for D-expression by flow cytometry using six human monoclonal IgG anti-D of the ALBAclone Advanced partial RhD typing kit (ALBA Bioscience), namely LHM169/ 81, LHM76/59, LHM76/55, LHM169/80, LHM57/17 and LHM76/58. Data analysis was performed with FlowJo Version 8 software (TreeStar, Ashland, OR, USA).
To measure mRNA levels of the transduced variants, RNA was isolated from 1 9 10 6 differentiated erythroblasts using TRIzol (Life Technologies, Paisley, UK) (Chomczynski & Sacchi, 1987) and 1 lg of RNA was used to synthesize cDNA using random hexamers (Invitrogen). Real-time quantitative reverse transcription PCRs (RQ-PCRs) were performed using the reporter dye SYBR-green (Sybrgreen Mastermix, Applied Biosystems) on a StepOnePlus (Applied Biosystems) with RHD-specific primers as listed in Table SI .
Results
A variant RHD allele is present in 0Á96% of Dutch Dpregnant women
Between 2011 and 2012, the fetal-RHD-genotyping assay, to determine whether anti-D prophylaxis is indicated, was performed on a total of 37 782 D-pregnant women. In 493 women (1Á3%) a maternal variant allele was suspected based on Ct-values and genetic follow-up was performed in 309 of these cases (Table SII) . Genetic follow-up was not performed in 184 cases due to (i) missing samples (n = 31); (ii) Ctvalues of around 31-32 (n = 83) and analysis in cases with stored DNA had shown that this is virtually always due to high fetal DNA levels and (iii) PCR results pointed to the presence of either RHD*Ψ or RHD*06 allele, as was shown in the first series of 159 cases with similar Ct values for exon 5 and exon 7 (Table I) .
In 39 (12Á6%) of the 309 evaluated D-pregnant women in whom genetic follow-up was performed, the RHD negativity was based on complete deletion of the RHD gene because the homozygous presence of the RHD*01N.01 allele was confirmed. In these cases the obtained Ct-values arose from high fetal RHD-DNA concentrations.
In the remaining 270 women a variant allele was identified (Table I ). The distribution of RHD alleles in these cases was used to calculate the distribution of RHD alleles in cases without follow-up (Table SII) . We estimate that 0Á96% (95% confidence interval [CI] 0Á86-1Á06%) of the Dutch serologically D-pregnant women had a variant allele containing RHD exon 5 and/or 7. The most frequently detected variant allele is the RHD*Ψ allele, which was present in 47% of the women carrying a variant RHD allele.
Pregnant D-women determined with standard serology carried at least 43 different variant alleles
In 218 of the 270 analysed cases carrying variant alleles and on whom genotyping were performed, the RH-MLPA genotyping assay directly identified a specific known RHD variant allele (listed in Table I ). In the remaining 52 cases (as indicated in Table I) (..) Cases where no extended serology could be performed. †The literature has described that the RHD*DEL5, RHD*DEL8 and RHD*DEL9 alleles cause the DEL phenotype (Singleton et al, 2001; Flegel et al, 2009; Reid et al, 2012) ; however, we detected a D-phenotype. ‡The literature indicates that RHD*01N.22 allele causes D-phenotype (Reid et al, 2012) ; however, we detected a DEL phenotype. §Novel variant allele. because the RH-MLPA typing results were inconclusive (n = 11) or indicated the presence of a normal RHD gene (n = 41). Sequencing of all RHD exons revealed the presence of previously described RHD variant alleles in 26 of these 52 cases. In the other 26 cases, 15 novel alleles were recognized (listed in Table III) , which were detected in single cases, except for the RHD*721A>C allele, detected in seven cases, and the RHD*1074-1G>A allele, detected in three cases (Table I ). In one case the novel RHD-RHCE-RHD allele could only be characterized by developing an MLPA containing seven new probes. In combination with the Ccddee phenotype and the results of the RHCE-MLPA, it was concluded (as explained in Fig S1) that this case most likely carries the known RHD*01N.03 allele (described to be associated with RhCe expression) and a novel allele in which RHD exon 1 is deleted (RHD*(2-10)). In one other case with a partial D expression in which the new allele could not be unambiguously be proven, we assume that the known RHD*10.01 and a novel RHD*[178A>C; 689G>T] allele are present instead of two novel alleles (RHD*689C>T and RHD*[178A>C; 689G>T; 1136C>T]). Remarkably, in three cases, all with the DEL phenotype and normal RhCE expression (RhCcee phenotype), an apparently normal wild-type RHD allele without mutations in the coding sequence, flanking introns and promoter region, was detected. In summary, a total of 43 different RHD variant alleles, including 15 novel RHD variant alleles, were identified in the 270 cases (Table I) .
Phenotype analysis of the fifteen novel variants using serology
Red blood cells from 259 cases (including all cases with novel variant alleles) out of the 270 cases with a variant RHD allele were available for additional serological analysis, including adsorption-elution. The initial D-phenotype was confirmed in 139 (54%) cases. In 33 (13%) cases a DEL phenotype, in 77 (30%) cases a partial D and in ten (4%) cases a weak D phenotype was determined (Table I ). The D-phenotype was confirmed for the novel alleles: RHD*1084C>T, RHD*124_125del and RHD*1174del (RHD*(2-10)) (RHD* 335G>T, RHD*[634+1G>T, 1136C>T], RHD*1073+1G>T and RHD*1074-1G>A) and the novel variant composed of the known RHD*03.03 and RHD*09.03.01 (Table III) .
The novel variants RHD*884T>C and RHD*721A>C caused the DEL phenotype (Table II) . The RHD*492C>A allele was serologically determined to lead to partial D expression, as epitope 5 (rD7C2) and epitope 8 (HIMA-36) were absent, whereas all other evaluated epitopes (including epitope 8 tested with LHM76/58) were detected (Table II) . Several anti-D MoAbs were only positive in the indirect agglutination test indicating that this variant allele has next to partial D also weakened D expression (data not shown). The RBC expressing the novel RHD*[178A>C; 689G>T] allele next to the known RHD*10.01 showed loss of epitopes 1, 5 and 8. However, as this corresponds to the epitope pattern for the RHD*10.01 allele , the exact phenotype of the new allele could not be determined (Table II) .
RhD epitope expression of the variants based on erythroblast expression system. Of the novel variant alleles the most surprising were the two variant alleles that caused the D-phenotype based on mutations that resulted in a single amino acid substitution or a single amino acid deletion in transmembrane regions of the RhD protein ( Fig S2) : the RHD*443C>G (encoding p.Thr148Arg) and RHD*424_426del (encoding p.Met142del) alleles (Table III) . We therefore applied our novel expression system, using transduced donor-isolated ccddee erythroblasts to confirm that the detected mutations were indeed solely responsible for the loss of expression. In addition, two other novel variant alleles, the partial RHD allele RHD*492C>A and the DEL allele RHD*721A>C were tested in this system. As a sensitivity control, and as a control for our expression system, the RHD*01W.02 and RHD*01 were also transduced (Fig 1) . RHD transcript levels, demonstrated that RHD mRNA levels did not significantly differ between RHD*01 and the RHD variants, indicating that the loss of expression was caused by the mutation and not by differences in transduction efficiency or RNA stability (Fig 2) . The erythroblast expression system confirmed the serological findings: the RHD*443C>G and the RHD*424_426del transcripts did not give rise to expression of any RhD epitope in erythroblasts (Table II and Fig 1) . The transduced erythroblasts confirmed the partial D phenotype of the RHD*492C>A allele, since LHM59/19 (targeting epitope 8.2) and RD7C2 (epitope 5) were completely negative and was not suggestive of severely weakened expression (Fig 2) . The RHD*721A>C allele (encoding p.Thr241Pro) was serologically determined to cause the DEL phenotype and this was confirmed in erythroblast expression system, even at lower expression levels when compared to the RHD*01W.02 allele (Fig 1) . Furthermore, only a few anti-D, LHM76/55 and LHM169/80 (targeting epitope 3 and 6/7 respectively) were detected as very weakly positive (Fig 1 and Table II ).
Discussion
In the present study we determined that a variant RHD allele containing RHD exon 5 and/or 7 is present in~0Á96% of the Dutch D-pregnant women. Genetic follow-up determined that almost half of the women with a variant allele carried the RHD*Ψ variant allele and about 16% carried one of the RHD*06 variants. All other detected RHD variants are rare and in total we identified 43 different variant alleles, including 15 novel RHD variant alleles. Extensive serological follow-up confirmed the D-phenotype in 54% of the women, but partial D expression was found in 29%, DEL expression in 14% and weak D expression in 4% of the women. In three cases we detected an apparently normal wild-type RHD allele IAT, indirect antiglobulin test; FACS, fluorescence-activated cell sorting. = heterozygous. ‡Position as counted from Met translation start site. §The case positive for this variant allele carried a second variant allele RHD*10.01 that causes partial D expression, therefore we cannot exclude that this variant allele can also cause the D-phenotype. yet a DEL phenotype was observed. Our analysis shows that in 0Á22% (95% CI 0Á17-0Á26%) of cases (excluding the women carrying the RHD*06 variants) serological typing incorrectly indicated RhD negativity. Conversely, RH-MLPA incorrectly predicted the D+ phenotype in 0Á05% (95% CI 0Á03-0Á08%) of serologically D-women.
Here we describe 15 novel alleles (11 D-null, two partialweak and two DEL alleles). The D-phenotype was determined for a novel allele with a nonsense mutation (RHD*1084C>T), two novel alleles with frame shift mutations (RHD*124_125del or RHD*1174del), four alleles with mutations that disrupt a splice site (RHD*335G>T, RHD*[634+1G>T, 1136C>T], RHD*1073+1G>T and RHD*1074-1G>A) and one allele with the deletion of exon 1 (RHD*(2-10)). The presence of this last allele could not be unambiguously proven, because of the presence of another variant allele in this case.
The D-phenotype was also determined for a variant allele that contained mutations of both the RHD*03.03 and RHD*09.03 variant alleles (RHD*[361T>A; 380T>C; 383A>G; 455A>C; 602C>G; 667T>G; 819G>A]). This was unexpected because the RHD*09.03 allele causes only a moderate weakening of the RhD expression and the RHD*03.03 allele has not been associated with an effect on RhD expression levels, although the mutations are all found in putative transmembrane and intra-cellular parts of the RhD protein, which might offer some explanation for our finding.
Interestingly, both an allele with a single missense mutation RHD*443C>G (encoding p.Thr148Arg) and an allele with the deletion of a single amino acid RHD*424_426del (p.Met142del) cause the D-phenotype, which was confirmed in a heterologous expression study in D-erythroblasts. Both alleles have mutations in the fifth putative transmembrane RhD expression levels of the RHD*424_426del, RHD*443C>G, RHD*492C>A and RHD*721A>C variant alleles in a heterologous expression assay. Overlay plots of the fluorescence intensity, representative for the RhD expression levels of RhD-negative erythroblasts transduced with constructs containing the RHD*424_426del, RHD*443C>G, RHD*492C>A, or RHD*721A>C and the well-described RHD*01W.02 cDNA (black line). The wild-type RHD*01 cDNA (black dashed line) was transduced for quantitative analysis of the expression levels. The RHD*01W.02 sensitivity control showed weakened RhD expression levels compared to the RHD*01 wild-type allele. The RHD*424_426del, RHD*443C>G alleles had completely no RhD expression, the RHD*492C>A allele had similar expression levels to the wild-type RHD*01 but showed weakened expression of epitope 3 (LHM76/55). The RHD*721A>C showed very weak expression of epitope 3 (LHM76/55) and epitope 6/7 (LHM 169/80) weakened RhD expression, even weaker than the RHD*01W.02 allele. Histograms are representative figures (n = 3). region of the RhD protein. Other RHD variant alleles with mutations in this region, show only drastically diminished D expression, for instance the RHD*01EL.07 (p.Ala137Glu) and RHD*01EL.12 (p.Leu153Pro) alleles (Flegel et al, 2009; Li et al, 2009 ). The mutations present in the transmembrane region may either influence RhD binding to RhAG and thereby disrupt the RhAG-RhD oligomer stability, or disrupt correct protein folding (Callebaut et al, 2006) .
The phenotype of the presumed novel partial RHD* [178A>C;689G>T] allele could not be unambiguously proven, because this allele was present next to the known RHD*10.01 allele and the observed epitope pattern (loss of epitopes 1, 5 and 8 and weakened D expression of the other epitopes) was similar to that described for RHD*10.01 . The c.689G>T mutation is responsible for the partial weak D phenotype in the known RHD*10.01 (RHD*[689G>T;1136C>T]) allele, because the RHD*10.00 (RHD*[1136C>T]) has normal RhD expression . This could mean that, for the case carrying the RHD*10.01 allele and the RHD*[178A>C;689G>T], the RHD*10.01 allele alone is responsible for this partial weak D phenotype but it is possible that the novel RHD* [178A>C;689G>T] variant results in a similar phenotype as both variants carry the c.689G>T (p.Ser230Ile) mutation.
The novel variant allele RHD*492C>A (p.Asp164Glu) equally caused partial weak D expression on RBCs and, also in the heterologous expression system, epitope 5 and part of epitope 8 were absent.
The novel RHD*721A>C allele (p.Thr241Pro) and RHD*884T>C (p.Met295Thr) with a single missense mutation in the transmembrane region of the RhD protein causes the DEL phenotype. Interestingly, the RHD*721A>C allele was detected in seven cases whereas all other novel alleles, except the RHD*1074-1G>A allele, were detected in single cases. This allele was not detected in previous studies performed in Germany, Austria, Poland and Belgium, respectively (Flegel et al, 2009; Polin et al, 2009; Orzinska et al, 2013; Van Sandt et al, 2015, respectively, indicating that this allele is specific for the Dutch population. All women positive for the RHD*721A>C allele had Dutch surnames but we have no indication that these women are related.
The DEL and RhCcee phenotype was detected in three cases with a wild-type RHD*01 allele and without any mutation in the intron boundaries or in the promoter region of the RHD gene. The RhCe expression was normal in these two cases. Flegel et al (2009) also described a single case without mutations in the RHD exons and intron boundaries with the DEL and a normal RhCe phenotype. Possibly, in these cases a deep intronic mutation is present or a gene that is required for membrane expression of the RhD protein is mutated.
Furthermore, it is important to note that for the variants RHD*DEL5, RHD*DEL8, RHD*DEL9, RHD*01N.22, the Dphenotype determined in this study deviated from previously reported DEL phenotypes (Singleton et al, 2001; Flegel et al, 2009; Reid et al, 2012) . A D-phenotype for RHD*DEL8 and RHD*DEL9 has been described (Wagner et al, 2001 ) and for RHD*DEL8, Kormoczi et al (2005) described a partial D phenotype. Moreover, in agreement with our observed D-serology is the fact that alloimmunization has occurred in individuals carrying the RHD*DEL8 Gardener et al, 2012) or the RHD*DEL5 (Daniels & Reid, 2010) allele.
Three large studies have been performed (46 133 Ddonors in Germany (Flegel et al, 2009) , 31 200 D-donors in Poland (Orzinska et al, 2013) and 23 330 D-donors Austria (Polin et al, 2009) ) to ascertain the presence of RHD variant alleles in D-donors, in which considerably lower percentages of D-donors carried RHD variant alleles, 0Á21%, 0Á20% and 0Á40%, respectively. The African RHD*Ψ allele was observed at low frequency (0Á03%) in the German donor population (Flegel et al, 2009 ) and not among the Austrian and Polish donors (Polin et al, 2009; Orzinska et al, 2013) . Furthermore, in our study the RHD*06 variant was tested as D-on purpose, while this was not the case in other studies. Even if the frequency of variant alleles in our study is recalculated excluding the RHD*Ψ and the RHD*06 alleles, 0Á32% (95% CI 0Á26-0Á37%) of the D-women carry an RHD variant: this is still slightly higher than the frequency in the two largest blood donor studies, possibly reflecting the multiracial origin of the Dutch pregnant population.
In conclusion, 0Á96% of the Dutch D-pregnant women carry a D variant allele harbouring RHD exon 5 and/or exon 7. The large majority of pregnant women with a variant allele carry an RH-null allele or partial RHD allele and need administration of anti-D prophylaxis to prevent anti-D immunization. Genotyping of this group of women has the RhD-transcript levels of D-transduced erythroblasts with the novel variants: RHD*424_426del, RHD*443C>G, RHD*492C>A and RHD*721A>C. Transcript levels of the various RHD mRNA show no significant differences between the novel variants or our sensitivity controls (RHD*01, RHD*01W.02) indicating that the fluorescenceactivated cell sorting results do not depend on different levels of viral transduction. Each dot represents one D-negative erythroblast donor. limited advantage in that the woman with weak D type 1, 2 and 3 are recognized and can be regarded in the current and any subsequent pregnancy as D+. More importantly, our study emphasizes the relevance of genotyping of blood donors (Denomme, 2013; Sandler et al, 2015) . Furthermore, this cohort of extensively typed D-women can be used to optimize RHD genotyping assays, as it is essential that the most frequently occurring D-null alleles are identified for correct prediction of the D phenotype via a genotyping assay Daniels, 2013b) .
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